Raymond James & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$3.01M	Sell	10,942 -5,315	-33%	-$1.38M	﹤0.01%	1972
2024 Q2	$3.95M	Buy	16,257 +1,089	+7%	+$172K	﹤0.01%	1756
2024 Q1	$2.27M	Buy	15,168 +882	+6%	+$147K	﹤0.01%	2085
2023 Q4	$2.73M	Buy	14,286 +1,875	+15%	+$319K	﹤0.01%	1905
2023 Q3	$2.2M	Buy	12,411 +598	+5%	+$114K	﹤0.01%	1966
2023 Q2	$2.24M	Buy	11,813 +1,230	+12%	+$244K	﹤0.01%	1984
2023 Q1	$2.12M	Sell	10,583 -534	-5%	-$112K	﹤0.01%	1999
2022 Q4	$2.64M	Buy	11,117 +500	+5%	+$107K	﹤0.01%	1819
2022 Q3	$2.13M	Sell	10,617 -5,524	-34%	-$1.05M	﹤0.01%	1924
2022 Q2	$2.35M	Sell	16,141 -16,919	-51%	-$2.4M	﹤0.01%	1891
2022 Q1	$5.4M	Sell	33,060 -10,443	-24%	-$1.59M	﹤0.01%	1459
2021 Q4	$7.38M	Buy	43,503 +3,802	+10%	+$707K	0.01%	1286
2021 Q3	$7.5M	Sell	39,701 -87	-0.2%	-$16.3K	0.01%	1234
2021 Q2	$6.75M	Buy	39,788 +3,157	+9%	+$462K	0.01%	1301
2021 Q1	$5.17M	Buy	36,631 +2,727	+8%	+$410K	0.01%	1410
2020 Q4	$4.41M	Buy	33,904 +2,261	+7%	+$302K	﹤0.01%	1410
2020 Q3	$4.61M	Buy	31,643 +1,018	+3%	+$145K	0.01%	1273
2020 Q2	$4.54M	Buy	30,625 +4,121	+16%	+$556K	0.01%	1246
2020 Q1	$2.88M	Buy	26,504 +24,540	+1,249%	+$2.83M	﹤0.01%	1360
2019 Q4	$226K	Buy	+1,964	New	+$196K	﹤0.01%	3269
2016 Q3	–	Sell	-4,008	Closed	-$222K	–	3218
2016 Q2	$222K	Buy	+4,008	New	+$253K	﹤0.01%	2589